MYC and acute lymphoblastic leukemia: Our study provides novel insight into the biochemical process underlying T-ALL metabolic reprogramming and facilitates a rational selection of adjunctive metabolic therapy in combination with CPI-613 to treat MYC-driven T-ALL and perhaps other MYC-driven cancers as well.